112 related articles for article (PubMed ID: 15241124)
1. Administration of nitric oxide synthase inhibitor 546C88 in septic shock.
Renes MH; van der Hoeven JG
Crit Care Med; 2004 Jul; 32(7):1625; author reply 1625-6. PubMed ID: 15241124
[No Abstract] [Full Text] [Related]
2. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
[TBL] [Abstract][Full Text] [Related]
3. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.
López A; Lorente JA; Steingrub J; Bakker J; McLuckie A; Willatts S; Brockway M; Anzueto A; Holzapfel L; Breen D; Silverman MS; Takala J; Donaldson J; Arneson C; Grove G; Grossman S; Grover R
Crit Care Med; 2004 Jan; 32(1):21-30. PubMed ID: 14707556
[TBL] [Abstract][Full Text] [Related]
4. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
[TBL] [Abstract][Full Text] [Related]
5. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.
Grover R; Zaccardelli D; Colice G; Guntupalli K; Watson D; Vincent JL
Crit Care Med; 1999 May; 27(5):913-22. PubMed ID: 10362413
[TBL] [Abstract][Full Text] [Related]
6. [Nitric-oxide synthase inhibitor treatment in septic shock].
Møller K; Skinhøj P
Ugeskr Laeger; 2004 Mar; 166(11):1028-9. PubMed ID: 15049244
[No Abstract] [Full Text] [Related]
7. [Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives].
Endres S; Eigler A
Internist (Berl); 1997 May; 38(5):466-9. PubMed ID: 9264984
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.
Hussein Z; Beerahee M; Grover R; Jordan B; Jeffs R; Donaldson J; Zaccardelli D; Colice G; Guntupalli K; Watson D; Vincent JL
Clin Pharmacol Ther; 1999 Jan; 65(1):1-9. PubMed ID: 9951425
[TBL] [Abstract][Full Text] [Related]
9. Relative contribution of preload and afterload to the reduction in cardiac output caused by nitric oxide synthase inhibition with L-N(G)-methylarginine hydrochloride 546C88.
Harrison RW; Thakkar RN; Senzaki H; Ekelund UE; Cho E; Kass DA; Hare JM
Crit Care Med; 2000 May; 28(5):1263-8. PubMed ID: 10834663
[TBL] [Abstract][Full Text] [Related]
10. Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red.
Cobb JP
Crit Care Med; 1999 May; 27(5):855-6. PubMed ID: 10362394
[No Abstract] [Full Text] [Related]
11. Effects of a nitric oxide synthase inhibitor in humans with septic shock.
Petros A; Lamb G; Leone A; Moncada S; Bennett D; Vallance P
Cardiovasc Res; 1994 Jan; 28(1):34-9. PubMed ID: 7509259
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of the activity of inducible nitric oxide synthase in septic shock.
Thiemermann C
Prog Clin Biol Res; 1995; 392():383-92. PubMed ID: 8524946
[No Abstract] [Full Text] [Related]
13. [Septic shock and NO].
Mitaka C
Nihon Rinsho; 2004 Sep; 62 Suppl 9():540-3. PubMed ID: 15506445
[No Abstract] [Full Text] [Related]
14. NO-synthase inhibition in sepsis.
Spiel AO; Mayr FB
Thromb Haemost; 2006 Apr; 95(4):591-2. PubMed ID: 16601826
[No Abstract] [Full Text] [Related]
15. Reversal of refractory hypotension in septic shock by inhibitor of nitric oxide synthase.
Lin PJ; Chang CH; Chang JP
Chest; 1994 Aug; 106(2):626-9. PubMed ID: 7539733
[TBL] [Abstract][Full Text] [Related]
16. Just say no to NO., yes?
Fink MP
Crit Care Med; 1996 Nov; 24(11):1772-4. PubMed ID: 8917023
[No Abstract] [Full Text] [Related]
17. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study.
Avontuur JA; Tutein Nolthenius RP; van Bodegom JW; Bruining HA
Crit Care Med; 1998 Apr; 26(4):660-7. PubMed ID: 9559602
[TBL] [Abstract][Full Text] [Related]
18. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock.
Petros A; Bennett D; Vallance P
Lancet; 1991 Dec 21-28; 338(8782-8783):1557-8. PubMed ID: 1720856
[TBL] [Abstract][Full Text] [Related]
19. Reinforcement therapy using nitric oxide synthase inhibitors against endotoxin shock in dogs.
Suga H; Nakagawa T; Soga Y; Deguchi Y; Suzuki T; Miyoshi N; Imamura Y; Fukuda M
Surg Today; 2006; 36(9):811-7. PubMed ID: 16937286
[TBL] [Abstract][Full Text] [Related]
20. Effect of the nitric oxide inhibitor, L-N(G)-monomethylarginine, on accumulation of interleukin-6 and interleukin-8, and nuclear factor-kappaB activity in a human endothelial cell line.
Galley HF; Nelson SJ; Dhillon J; Dubbels AM; Webster NR
Crit Care Med; 1999 May; 27(5):908-12. PubMed ID: 10362412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
